Deals this week: Google, Valeritas, Vapotherm

16 November 2018 (Last Updated November 16th, 2018 12:46)

Google has opted to integrate its sister company DeepMind’s health technology unit with its newly formed health subsidiary, Google Health.

Google has opted to integrate its sister company DeepMind’s health technology unit with its newly formed health subsidiary, Google Health.

The team that developed Streams, a mobile patient care app at DeepMind, will join Google Health. The app helps doctors in providing better healthcare to patients.

The app will be now upgraded as an artificial intelligence (AI)-powered assistant for doctors and nurses.

Valeritas has entered a distribution agreement with Julphar to commercialise the former’s flagship V-Go wearble insulin delivery device in the Gulf Cooperation Council (GCC).

Under the agreement, Julphar holds the right to the promotion, marketing and selling of V-Go to diabetes clinics and patients in the GCC, while Valeritas will be responsible for its development, regulatory approval, quality check, and manufacturing.

Valeritas is a medical technology company based in the US, while Julphar is a pharmaceutical company based in the UAE.

US-based medical technology company Vapotherm has announced the pricing of its initial public offering (IPO) of four million shares of common stock priced at $14 a share.

The company has additionally provided underwriters a 30-day option to buy up to 600,000 shares of common stock.

“The company has additionally provided underwriters a 30-day option to buy up to 600,000 shares of common stock.”

Nyxoah has raised an additional €15m ($17.1m) funding in a fresh equity round led by Cochlear.

The new funding brings Cochlear total funding to Nyxoah to €13m ($14.72m).

Funding will be used to support the post-CE Mark developmental activities of Nyxoah’s BLAST-OSA (BiLAteral Hypoglossal Nerve Stimulation) for treatment of obstructive sleep apnoea in Europe and to gain investigational device exemption from the US Food and Drug Administration (FDA).

Nyxoah is based in Belgium, while Cochlear is headquartered in Australia.

GN Hearing has expanded its Smart Hearing Alliance with Cochlear for the development of new hearing products to aid moderate to profound hearing loss.

Under the new agreement, research and development activities will be monitored jointly and technologies will be mutually shared to improve their integrity to expand the reach of clinical and implantable hearing solutions.

GN Hearing is a medical device company based in the US.